Engineering the Future of Cancer Drug Discovery
Raising $2M Pre-Seed
Introducing LURA
The Computational Barrier in Oncology
$2.6B + 12+ years per drug. Most oncology candidates still fail. Why? Tools give probabilities — not why a drug works in one context but fails in another.
Elyris Labs Ends the Guesswork
LURA delivers causal mechanistic insight into real tumor biology — explaining why compounds succeed or fail. Stop wasting experiments. Start advancing drugs that actually work.
Platform Performance
LURA accelerates and de-risks cancer drug discovery and relational mapping with validated, mechanistic simulation.
Why These Numbers Matter
Traditional oncology discovery wastes billions on candidates that fail due to unmodeled 3D barriers and mechanisms. LURA's physics + AI approach cuts through that — delivering 10–20× faster insights, validated accuracy, and sub-second responses so teams focus on winners.
Aanu Oshakuade
Co-Founder/CEO | Computer Engineering | AI/ML
Elisha Sannousi
Co-Founder | Clinical & Translational Engineer (M.S. Translational Medicine, Bioengineering)
Samuel Tandeka
Co-Founder | Engineering Management & Business Development (M.S. Engineering Management) (B.S. Electrical Eng.)
//00 FAQ
LURA Explained
The core questions partners and researchers ask about our 3D neural engine — and how it accelerates cancer drug discovery.
What is LURA?
LURA is a production-scale 3D physics engine for cancer drug discovery. It builds full, configurable virtual tumor microenvironments and runs millions of virtual experiments to show what actually works — and why — before any wet-lab spend.
Does LURA handle different cancer stages and metastasis?
Yes. Stage I and Stage IV of the same tumor type have completely different parameters — hypoxia, EMT, immune evasion, glucose dependency, etc. Metastatic behavior and TME composition are modeled as distinct, differentiable states so you see exactly how progression changes drug response.
What can I actually test with LURA?
Single agents and full dose-response curves Drug combinations and sequencing Timing & scheduling (e.g., 3 days on, 4 days off) Custom mutations, TME compositions, hypoxia levels, or patient-derived profiles Mechanistic “why it failed” explanations and pathway impacts Rapid repurposing screens across multiple indications
Is the system validated on real cancers and drugs?
Yes — built and tested against hundreds of thousands of historical drug-tumor response measurements across diverse solid tumors. It reproduces known clinical patterns and explains documented failures with clear, physics-based reasoning
How accurate and fast is LURA?
LURA achieves 80–88% correlation with real biological outcomes while delivering hundreds of full 3D tumor simulations per second. A 1,000-compound screen on one tumor model finishes in under 2 minutes; millions of experiments run in hours.
How easy is it for wet-lab teams to use?
Extremely. The V5 dashboard requires no coding. Select or upload your tumor context, choose compounds, run simulations, and get interactive 3D views, dose curves, and plain-English mechanistic summaries. Results are reproducible and ready to share with your team.